Second, while ML29P50 and ML29 induced comparable T cell responses at day 7, at the late stage of the infection ML29P50 generated much stronger T cell immunity as assessed by IFN-ɣ/IL-2 ELISPOT in line with the strong immunomodulation potency of defective IPs [82]. This evidence concerns the gene IL2 and infection.